{"id":2995,"date":"2018-08-16T18:13:07","date_gmt":"2018-08-16T12:43:07","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2995"},"modified":"2021-07-24T12:57:01","modified_gmt":"2021-07-24T07:27:01","slug":"the-business-cocktail-therapeutics","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-therapeutics","title":{"rendered":"The Business Cocktail(Therapeutics)"},"content":{"rendered":"
Blueberry Therapeutics<\/b>\u00a0reels in USD\u00a012.7 Million in series B funding for fungal infections.<\/b><\/span><\/div>\n
<\/div>\n
U.K.based,\u00a0Blueberry Therapeutics<\/b>\u00a0successfully bagged a funding of USD\u00a012.7 million in series B funding. The funding will help the company to advance its nanomedicine\u00a0candidate,\u00a0BB2603<\/b>\u00a0for two fungal infections namely-\u00a0Athlete\u2019s foot and fungal nail infections.\u00a0BB2603<\/b>\u00a0is a nanoformulated form of\u00a0terbinafine,\u00a0which is an antifungal treatment, it is currently in the phase 2 and is expected to enter the phase 3 soon after the funding.\u00a0\u00a0<\/span><\/div>\n
\n
<\/div>\n

Pfizer remunerates\u00a0Germany\u2019s\u00a0BioNTech $120M for forming mRNA flu vaccine agreement.<\/strong><\/span><\/p>\n<\/div>\n

Pfizer\u00a0reimburses\u00a0a $425 million deal for working with BioNTech to produce mRNA influenza vaccines. To get into R&D association, the Big Pharma, Pfizer is providing $120 million\u00a0 beforehand and near-term payments.
\nIn\u00a0mRNA field,\u00a0BioNTech spearheads that heads to deals with\u00a0Sanofi,\u00a0Eli Lilly\u00a0andGenentech and a $270 million series A.<\/span><\/span><\/div>\n
\n

Orchard has grabbed USD 150 Million in Series C funding for multifront late-phase gene therapy.<\/b><\/p>\n<\/div>\n

Orchard Therapeutics has snatched a whooping sum of USD\u00a0150 Million in Series C funding round to proceed three gene therapies towards approval. Orchard has maintained the transformative steak started in the first half of this year with GSK gene therapies acquisition, including the less used approved drug, Strimvelis<\/strong>. The funding will help in the growth and development of the expanded company pipeline<\/a>.<\/span><\/span><\/div>\n
\n

Artios<\/b>\u00a0<\/b>Pharma<\/b>\u00a0<\/b>secured USD 84 Million for clinical trials of next generation DNA damage response drugs<\/a>\u00a0.<\/b><\/p>\n

U.K. based\u00a0pharmaceutical company, Artios Pharma has\u00a0recently bagged USD\u00a084 Million for accelerating its DNA damage response (DDR) programs in clinical trails.\u00a0Artios Pharma entered into the DDR programs after in-licensing it from Cancer Research Technology in 2016.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Blueberry Therapeutics\u00a0reels in USD\u00a012.7 Million in series B funding for fungal infections. U.K.based,\u00a0Blueberry Therapeutics\u00a0successfully bagged a funding of USD\u00a012.7 million in series B funding. The funding will help the company to advance its nanomedicine\u00a0candidate,\u00a0BB2603\u00a0for two fungal infections namely-\u00a0Athlete\u2019s foot and fungal nail infections.\u00a0BB2603\u00a0is a nanoformulated form of\u00a0terbinafine,\u00a0which is an antifungal treatment, it is currently in […]<\/p>\n","protected":false},"author":1,"featured_media":1914,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1696,1700,1695,137,1699,215,258,1698,1697,460,1151,569],"industry":[17225],"therapeutic_areas":[17235,17231],"class_list":["post-2995","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-artios-pharma","tag-bb2603","tag-blueberry-therapeutics","tag-cancer","tag-ddr","tag-dna","tag-gene-therapy","tag-mrna-flu","tag-orchard","tag-pfizer","tag-strimvelis","tag-therapeutics","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-infectious-diseases"],"acf":[],"yoast_head":"\nThe Business Cocktail(Therapeutics) - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"Blueberry Therapeutics\u00a0reels in USD\u00a012.7 Million in series B funding for fungal infections.U.K.based,\u00a0Blueberry Therapeutics\u00a0successfully......\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-therapeutics\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Business Cocktail(Therapeutics) - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"Blueberry Therapeutics\u00a0reels in USD\u00a012.7 Million in series B funding for fungal infections.U.K.based,\u00a0Blueberry Therapeutics\u00a0successfully......\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-therapeutics\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-08-16T12:43:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021341\/business-cocktail.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1100\" \/>\n\t<meta property=\"og:image:height\" content=\"618\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"The Business Cocktail(Therapeutics) - DelveInsight Business Research","description":"Blueberry Therapeutics\u00a0reels in USD\u00a012.7 Million in series B funding for fungal infections.U.K.based,\u00a0Blueberry Therapeutics\u00a0successfully......","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-therapeutics","og_locale":"en_US","og_type":"article","og_title":"The Business Cocktail(Therapeutics) - DelveInsight Business Research","og_description":"Blueberry Therapeutics\u00a0reels in USD\u00a012.7 Million in series B funding for fungal infections.U.K.based,\u00a0Blueberry Therapeutics\u00a0successfully......","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-therapeutics","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-08-16T12:43:07+00:00","article_modified_time":"2021-07-24T07:27:01+00:00","og_image":[{"width":1100,"height":618,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021341\/business-cocktail.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-therapeutics","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-therapeutics","name":"The Business Cocktail(Therapeutics) - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-therapeutics#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-therapeutics#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021341\/business-cocktail.jpg","datePublished":"2018-08-16T12:43:07+00:00","dateModified":"2021-07-24T07:27:01+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Blueberry Therapeutics\u00a0reels in USD\u00a012.7 Million in series B funding for fungal infections.U.K.based,\u00a0Blueberry Therapeutics\u00a0successfully......","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-therapeutics"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-therapeutics#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021341\/business-cocktail.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021341\/business-cocktail.jpg","width":1100,"height":618,"caption":"Therapeutics"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021341\/business-cocktail-300x169.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">artios pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">BB2603<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Blueberry Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DDR<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DNA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gene therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">mRNA flu<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">orchard<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Strimvelis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">therapeutics<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">artios pharma<\/span>","<span class=\"advgb-post-tax-term\">BB2603<\/span>","<span class=\"advgb-post-tax-term\">Blueberry Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">DDR<\/span>","<span class=\"advgb-post-tax-term\">DNA<\/span>","<span class=\"advgb-post-tax-term\">Gene therapy<\/span>","<span class=\"advgb-post-tax-term\">mRNA flu<\/span>","<span class=\"advgb-post-tax-term\">orchard<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">Strimvelis<\/span>","<span class=\"advgb-post-tax-term\">therapeutics<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Aug 16, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Aug 16, 2018 6:13 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2995","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2995"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2995\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1914"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2995"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2995"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2995"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2995"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2995"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}